Featured News See All October 29, 2026 REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights October 12, 2026 REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 September 24, 2026 REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 Oct 29, 2026 REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights Oct 12, 2026 REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 Sep 24, 2026 REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting Sep 08, 2026 REGENXBIO to Participate in Upcoming Investor Conferences Aug 25, 2026 REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli Aug 24, 2026 REGENXBIO Announces Regulatory Update on RGX-121 for MPS II Aug 06, 2026 REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
Oct 29, 2026 REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
Oct 12, 2026 REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
Sep 24, 2026 REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
